Biochemical markers of bone metabolism and bone mineral density in patients with type 2 diabetic foot ulcer.
Xu T., Sun Y., Huang P., Shi R., Yang J., Gu Y.
Prospective Study with a reported sample of 400 on Type 2 Diabetes, Diabetic Foot, published in BMC Endocr Disord (2026) — summary generated from the PubMed abstract.
This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.
- Study type
- Prospective Study
- Journal
- BMC Endocr Disord (2026)
- Country
- England
- Reported sample size
- 400
- PMID
- 42210208
- DOI
- 10.1186/s12902-026-02328-5
Abstract (original English)
Type 2 diabetic foot ulcer (DFU) is closely linked to disorders of bone metabolism and abnormal bone mineral density (BMD), while serum 25-hydroxyvitamin D [25(OH)D], the gold standard for evaluating Vit D nutritional status, acts as an independent protective factor for DFU and is implicated in skeletal health regulation in diabetic patients. This cross-sectional study aimed to investigate biochemical markers of bone metabolism and BMD in patients with type 2 diabetic foot ulcer, and to identify risk factors for diabetic foot and accompanying gangrene. A total of 400 patients with type 2 diabetes mellitus (T2DM) admitted to the Endocrinology Ward of Affiliated Hospital of Nantong University from December 2021 to May 2023 were enrolled, including 155 in the DF group and 245 in the non-diabetic foot (NDF) group. Clinical data, bone metabolism markers and BMD measured by dual-energy X-ray absorptiometry (DXA) were collected, and data were analyzed using SPSS 25.0 software. Compared with the NDF group, the DF group had older age, longer diabetes duration, higher systolic blood pressure (SBP), urinary albumin creatinine ratio (UACR) and type I collagen N-terminal propeptide (PINP) level, but lower levels of serum albumin (ALB), glycemic and lipid indicators, 25(OH)D, total BMD and hip regional B < 0.05), with a significantly higher prevalence of low bone mass and osteoporosis. Binar
What this study does not prove
- • This study does not prove SVF is an approved treatment or a replacement for standard care.
Evidence level
Early human evidence such as case series or small samples, often without a control group.
How we grade evidenceRelated research
- Level ASystematic Review
Systematic Review: Exosomes as Molecular Messengers in the Development of Obesity-Related Complications in Children.
Systematic Review on Type 2 Diabetes, published in Curr Issues Mol Biol (2025) — summary generated from the PubMed abstract.
- 2025
Curr Issues Mol Biol - Level AMeta-analysis
Type 2 Diabetes Mellitus Induced Paracrine Effects on Breast Cancer Metastasis Through Extracellular Vesicles Derived from Human Mesenchymal Stem Cells.
Meta-analysis on Type 2 Diabetes, published in Stem Cells Dev (2020) — summary generated from the PubMed abstract.
- 2020
Stem Cells Dev - Level ASystematic Review
Adipose-derived Mesenchymal Stem Cells in the Treatment of Obesity: A Systematic Review of Longitudinal Studies on Preclinical Evidence.
Systematic Review on Type 2 Diabetes, published in Curr Stem Cell Res Ther (2018) — summary generated from the PubMed abstract.
- 2018
Curr Stem Cell Res Ther - Level AMeta-analysis
Metabolic effects of large-volume liposuction for obese healthy women: a meta-analysis of fasting insulin levels.
Meta-analysis on Type 2 Diabetes, published in Aesthetic Plast Surg (2014) — summary generated from the PubMed abstract.
- 2014
Aesthetic Plast Surg - Level BClinical Trial
Safety and efficacy of autologous adipose tissue-derived stem cell transplantation in aging-related low-grade inflammation patients: a single-group, open-label, phase I clinical trial.
Clinical Trial on Type 2 Diabetes, Neuroinflammation, Immune Modulation, published in Trials (2024) — summary generated from the PubMed abstract.
- 2024
Trials - Level BRandomized Controlled Trial
Using adipose-derived mesenchymal stem cells to fight the metabolic complications of obesity: Where do we stand?
Randomized Controlled Trial on Type 2 Diabetes, Immune Modulation, published in Obes Rev (2022) — summary generated from the PubMed abstract.
- 2022
Obes Rev